Locoregional Therapies in Melanoma

Surgical Clinics of North America

Volumn 94, Issue 5, 2014, Pages 1003-1015

  Abbott, Andrea M ^a   Zager, Jonathan S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Hyperthermic isolated limb perfusion; Intra tumoral injections; Isolated limb infusion; Locoregional recurrence; Melanoma

Indexed keywords

BCG VACCINE; DACTINOMYCIN; DIPHENCYPRONE; IMIQUIMOD; INTERLEUKIN 2; MELPHALAN; ROSE BENGAL; TALIMOGENE LAHERPAREPVEC; TUMOR NECROSIS FACTOR ALPHA; ALKYLATING AGENT; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT;

ARTERY PERFUSION; CANCER RADIOTHERAPY; HUMAN; HYPERTHERMIC THERAPY; LIMB PERFUSION; MELANOMA; METASTATIC MELANOMA; MYCOBACTERIUM BOVIS BCG; NONHUMAN; REGIONAL PERFUSION; REVIEW; SYSTEMIC THERAPY; GENE THERAPY; HYPERTHERMIC ISOLATED LIMB PERFUSION; INTRA-TUMORAL INJECTIONS; INTRALESIONAL DRUG ADMINISTRATION; ISOLATED LIMB INFUSION; LOCOREGIONAL RECURRENCE; METHODOLOGY; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR; TUMOR RECURRENCE;

HYPERTHERMIC ISOLATED LIMB PERFUSION; INTRA-TUMORAL INJECTIONS; ISOLATED LIMB INFUSION; LOCOREGIONAL RECURRENCE; MELANOMA;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS, ALKYLATING; BCG VACCINE; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; GENETIC THERAPY; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MELANOMA; NEOPLASM RECURRENCE, LOCAL; ROSE BENGAL; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84907669359     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.07.004     Document Type: Review

References (51)

1. National Comprehensive Cancer Network. Melanoma. Version 3.2014. Available at: . Accessed July 30, 2014. http://www.nccn.org.
2. Balch C.M., Gershenwald J.E., Soong S., et al. Final version of 2009 AJCC melanoma staging and classification. JClin Oncol 2009, 27:6199-6206.
3. Pawlik T.M., Ross M.I., Johnson M.M., et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005, 12:587-596.
4. Coit D.G., Andtbacka R., Anker C.J., et al. Melanoma. JNatl Compr Canc Netw 2012, 10:366-400.
5. Squires M.H., Delman K.A. Current treatment of locoregional recurrence of melanoma. Curr Oncol Rep 2013, 15:465-472.
6. Dong X.D., Tyler D., Johnson J.L., et al. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 2000, 88:1063-1071.
7. Yao K.A., Hsueh E.C., Essner R., et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?. Ann Surg 2003, 238:743-747.
8. Beasley G.M., Speicher P., Sharma K., et al. Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. JAm Coll Surg 2014, 21:1435-1440.
9. Creech O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958, 148:616-632.
10. Fraker D.L. Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol 2004, 5:173-184.
11. Fraker D.L. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999, 36:841-907.
12. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004, 139:1237-1242.
13. Kroon B.B., Noorda E.M., Vrouenraets B.C., et al. Isolated limb perfusion for melanoma. JSurg Oncol 2002, 79:252-255.
14. Eggermont A.M., Schraffordt Koops H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996, 224:756-764. [discussion: 764-5].
15. Cornett W.R., McCall L.M., Petersen R.P., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. JClin Oncol 2006, 24:4196-4201.
16. Lienard D., Eggermont A.M., Schraffordt Koops H., et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994, 4(Suppl 1):21-26.
17. Fraker D.L., Alexander H.R., Andrich M., et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. JClin Oncol 1996, 14:479-489.
18. Moller M.G., Lewis J.M., Dessureault S., et al. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008, 24:275-289.
19. Weiberdink J., Benckhuvsen C., Braat R.P., et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982, 18:905-910.
20. Eggimann P., Chiolero R., Chassot P.G., et al. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 1995, 107:1074-1082.
21. Sorkin P., Abu-Abid S., Lev D., et al. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1995, 130:1079-1084.
22. Beasley G.M., Petersen R.P., Yoo J., et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008, 15:2195-2205.
23. Raymond A.K., Beasley G.M., Broadwater G., et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. JAm Coll Surg 2011, 213:306-316.
24. Kroon H.M., Moncrieff M., Kam P.C., et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008, 15:3003-3013.
25. Thompson J.F., Kam P.C., Waugh R.C., et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998, 14:238-247.
26. Beasley G.M., Caudle A., Petersen R.P., et al. Amulti-institutional experience of isolated limb infusion: defining response and toxicity in the US. JAm Coll Surg 2009, 208:706-715. [discussion: 715-7].
27. Santillan A.A., Delman K.A., Beasley G.M., et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009, 16:2570-2578.
28. Chai C.Y., Deneve J.L., Beasley G.M., et al. Amulti-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 2012, 19:1637-1643.
29. Kroon H.M., Lin D.Y., Kam P.C., et al. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer 2009, 115:1932-1940.
30. Morton D.L., Eilber F.R., Holmes E.C., et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974, 180:635-643.
31. Agarwala S.S., Neuberg D., Park Y., et al. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 2004, 100:1692-1698.
32. Radny P., Caroli J.M., Bauer J., et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003, 89:1620-1626.
33. Elias E.G., Sharma B.K. Consequential administration of intralesional (intratumoral) GM-CSF and IL-2 in the management of metastatic and primary invasive cutaneous melanoma. JClin Oncol 2013, (Suppl). [abstract: e20052].
34. Toomey P., Kodumudi K., Weber A., et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One 2013, 8:e68561.
35. Thompson J.F., Hersey P., Wachter E. Chemoablation of metastatic melanoma using intralesional rose Bengal. Melanoma Res 2008, 18:405-411.
36. Agarwala SS, Thompson JF, Smithers BM, etal. Locoregional disease control in metastatic melanoma: exploratory analysis from phase 2 testing of intralesional rose Bengal. ECCO-ESMO-ESTRO Congress. Amsterdam, September 2013 [abstract: 3755].
37. Agarwala S.S., Thompson J.F., Smithers B.M., et al. Chemoablation of metastatic melanoma with rose bengal (PV-10). JClin Oncol 2010, 28(Suppl):15s. [abstract: 8534].
38. Agarwala S.S., Thompson J.F., Smithers B.M., et al. Chemoablation of melanoma with intralesional rose Bengal (PV-10). JClin Oncol 2009, (Suppl). [abstract: 9060].
39. Senzer N.N., Kaufman H.L., Amatruda T., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. JClin Oncol 2009, 27:5763-5771.
40. Andtbacka R.H., Collichio F.A., Amatruda T., et al. OPTiM: a randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. JClin Oncol 2013, 31(Suppl). [abstract: LBA9008].
41. Andtbacka RH, Ross MI, Delman K, etal. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM study and the contribution of surgery to response. Society of Surgical Oncology Annual Meeting. Phoenix, March 2014.
42. Ellis L.Z., Cohen J.L., High W., et al. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature. Dermatol Surg 2012, 38:937-946.
43. Berman B., Poochareon V.N., Villa A.M. Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Therapy Lett 2002, 7:1-6.
44. Florin V., Desmedt E., Vercambre-Darras S., et al. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs 2012, 30:1641-1645.
45. Damian D.L., Saw R.P., Thompson J.F. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. JSurg Oncol 2014, 109:308-313.
46. Sause W.T., Cooper J.S., Rush S., et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991, 20:429-432.
47. Seegenschmiedt M.H., Keilholz L., Altendorf-Hofmann A., et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999, 44:607-618.
48. Olivier K.R., Schild S.E., Morris C.G., et al. Ahigher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 2007, 110:1791-1795.
49. Konefal J.B., Emami B., Pilepich M.V. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987, 164:607-610.
50. Coventry B.J., Kroon H.M., Giles M.H., et al. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. JSurg Oncol 2014, 109(8):780-785. 10.1002/jso.23590.
51. Wong J., Chen Y.A., Fisher K.J., et al. Isolated limb infusion in a series of over 100 infusions: a single-center experience. Ann Surg Oncol 2013, 20(4):1121-1127. 10.1245/s10434-012-2782-8.